Quick Takeaways
- PRICE T ROWE ASSOCIATES INC /MD/ filed SCHEDULE 13G for MOONLAKE IMMUNOTHERAPEUTICS COMMON STOCK (MLTX).
- Disclosed ownership: 5.3%.
- Date of event: 31 Dec 2024.
PRICE T ROWE ASSOCIATES INC /MD/ - 31 Dec 2024 SCHEDULE 13G Report for MOONLAKE IMMUNOTHERAPEUTICS COMMON STOCK (MLTX)
- Filing Manager
- PRICE T ROWE ASSOCIATES INC /MD/
- Reporting Manager
- T. Rowe Price Associates, Inc.
- Symbol
- MLTX
- Shares outstanding
- 63,087,604 shares
- Disclosed Ownership
- 3,343,643 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 09:44:09 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 14 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PRICE T ROWE ASSOCIATES INC /MD/ disclosed 5.3% ownership in MOONLAKE IMMUNOTHERAPEUTICS COMMON STOCK (MLTX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 09:44.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| T. Rowe Price Associates, Inc. | 5.3% | 3,343,643 | 3,309,301 | 0 | Ellen York | Vice President |